Blog

Namandjé N. Bumpus, Ph.D.

Dr. Namandjé N. Bumpus joined F-Prime in 2025, where she serves as a strategic advisor on regulatory science, regulatory affairs, and policy, bringing deep expertise from her previous roles as FDA Principal Deputy Commissioner and Chief Scientist. Before the FDA, Dr. Bumpus was the E.K. Marshall and Thomas H. Maren Professor and director of the Department of Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine, where her research advanced understanding of drug metabolism, mechanisms of drug-induced toxicity, pharmacogenetics, bioanalytical chemistry, infectious disease pharmacology, and single cell biology. She completed her postdoctoral fellowship at The Scripps Research Institute and holds a PhD in pharmacology from the University of Michigan and a bachelor’s degree in biology from Occidental College.

Dr. Bumpus is a past-president of the American Society for Pharmacology and Experimental Therapeutics, a fellow of the American Association for the Advancement of Science, and a member of the National Academy of Medicine.

Catherine Stehman-Breen

Catherine Stehman-Breen is a Venture Partner at F-Prime based in the Cambridge office, focusing on new company creation. She has more than 30 years of medical and biopharmaceutical experience. Prior to joining F-Prime, Catherine was CEO of Chroma Medicine, a company developing a novel epigenetic editing therapeutics platform where she built the company from inception. Previously, she was Chief Research and Development Officer at Obsidian Therapeutics, a cell therapy company developing engineered tumor infiltrating lymphocyte therapies for patients with solid tumors. As Entrepreneur in Residence at Atlas Venture, she worked closely with start-ups across a range of technologies and previously served as Chief Medical Officer at Sarepta Therapeutics. In addition, Catherine held various leadership roles at Regeneron and Amgen.

Catherine earned her M.D. from the University of Chicago. She completed her residency and nephrology fellowship training at the University of Washington, where she also received an M.S. in epidemiology. Catherine served as a faculty member in the division of nephrology and remains an affiliate associate professor in the University of Washington School of Public Health, with more than 90 publications in medical journals.

Laurus Bio

Laurus Bio is an integrated research-driven biomanufacturing organization specializing in precision fermentation and recombinant technology. They develop sustainable, animal-free proteins and growth factors, replacing animal-derived products in various industries. Laurus Bio also offers CDMO services for microbial fermentation-based manufacturing and product development.

Countable Labs

Countable Labs is redefining PCR with single-molecule precision and category-defining sensitivity, overcoming the limitations of legacy technologies. Countable PCR delivers 10 times the sensitivity and precision of digital PCR in a single reaction. Plus, it speeds up assay development with simplified multiplexing. These breakthroughs unlock high-sensitivity applications that were previously impractical due to cost and complexity.

Insmed

Insmed Incorporated is a biopharmaceutical firm focused on developing therapies for serious and rare diseases, including respiratory and inflammatory conditions. Its flagship product, Arikayce, targets treatment-refractory Mycobacterium avium complex lung disease.

Peptone

Peptone is an innovative drug discovery company applying advanced biophysics, atomic-level experimental approaches, cutting-edge supercomputing and machine learning to the challenge of biopharmaceutical research and development. By bringing these proprietary approaches together, Peptone is exploring the world of intrinsically disordered proteins (IDPs) – proteins without a fixed structure that play a significant role in health and disease – opening up the possibility of novel therapeutics against this class of high value and previously undruggable targets.

Pioneering Progress: The Vyndaqel®/Vyndamax™ Story

The approval of Vyndaqel®/Vyndamax™ is paving the way for an expanding landscape of approved and investigational treatments for transthyretin amyloid diseases.

F-Prime is dedicated to advancing pioneering science and technologies that redefine patient care and treatment. Since 2002, F-Prime has facilitated the regulatory approval and commercialization of 33 products and drugs. In this series, Pioneering Progress, we showcase success stories behind the approval of drugs and products from our portfolio companies.

Understanding Transthyretin Amyloidosis, a Rare and Fatal Disease

Transthyretin amyloidosis (ATTR amyloidosis) is a rare, progressive, and fatal disease caused by the accumulation of misfolded proteins, known as amyloid, in the peripheral nervous system, heart, and other organs. This occurs when transthyretin (TTR)—a protein that transports the thyroid hormone thyroxine and retinol—misfolds and forms amyloid deposits. Normally, TTR exists as a tetramer, a stable cluster of four identical protein units. However, with aging or inherited mutations, these units separate and misfold, resulting in the formation of harmful amyloid fibrils, which are insoluble and resistant to degradation. ATTR amyloidosis manifests in several forms, with the two most common types being ATTR amyloidosis polyneuropathy (ATTR-PN), which affects the nerves, and ATTR cardiomyopathy (ATTR-CM), which impacts the heart.

ATTR-PN, which is estimated to affect 10,000-40,000 patients globally, leads to amyloid fibril-based damage to nerves, resulting in muscle weakness, loss of sensation, tingling, numbness, pain, and digestive track issues.1, 2, 3 Without prompt intervention, ATTR-PN is typically fatal within 10 years and, until recently, the only effective treatment was liver transplantation.2

ATTR-CM, on the other hand, is characterized by amyloid fibril accumulation in the heart tissue and results in symptoms resembling that of other heart conditions such as heart failure, further complicating diagnosis.3 While ATTR-CM was once considered very rare due to the diagnostic difficulty, recent improvements in diagnostic techniques have significantly increased incidence estimates, now with 5,000-7,000 new cases identified annually in the US alone4. Historically, individuals with ATTR-CM faced a poor prognosis, often experiencing severe health complications and a high risk of death within two to six years of diagnosis.5

With limited treatment options that target the root cause of ATTR amyloidosis, F-Prime saw a tremendous opportunity to bring new therapies to patients and transform how these diseases are treated and understood.

Advancing the Fight Against ATTR Amyloidosis

 The understanding of ATTR amyloidosis took a major step forward with the work of Portuguese physician and leading ATTR amyloidosis researcher Teresa Coelho, Ph.D., who linked mutations in the TTR gene to the development of amyloid disease. Her research identified key disease-causing mutations, such as V30M and V122I, and uncovered a secondary mutation that interestingly led to TTR tetramer stabilization and better patient outcomes. Building on these findings, Jeff Kelly, Ph.D., a chemist at Scripps Research Institute and co-founder of FoldRx, proposed a new treatment approach—a small molecule drug designed to stabilize TTR and prevent misfolding.

By screening known drugs and applying structure-based drug design, Kelly’s team discovered Vyndaqel/Vyndamax, a small molecule drug that binds to TTR. By keeping the protein in its stable tetramer form, this approach helps prevent TTR from breaking apart, misfolding, and forming harmful amyloid deposits. With a unique molecule and promising early data, Kelly co-founded FoldRx in 2003 together with Susan Lindquist, Ph.D., former director of the Whitehead Institute for Biomedical Research.

“FoldRx came to us with a strong foundation of peer-reviewed scientific research supporting its hypothesis and a simple but innovative approach for addressing ATTR amyloidosis that offered curative potential,” said Stephen Knight, M.D., President and Senior Managing Partner at F-Prime. “Their solution made FoldRx an ideal investment opportunity that closely aligned with F-Prime’s goal to fund companies with transformative potential. Together, we were able to lay the foundation for Vyndaqel/Vyndamax’s eventual approval and bring forward a much-needed therapy for this life-threatening disease.”

Under the leadership of CEO Richard Labaudiniere, Ph.D., FoldRx initiated clinical development of Vyndaqel/Vyndamax, starting with a Phase 0 study to better characterize the typical ATTR-PN patient natural history—which at the time was entirely unknown—and continuing through completion of a Phase 2 study.

Based on encouraging data from the Phase 2 study, Pfizer acquired FoldRx and Vyndaqel/Vyndamax received European marketing approval in 2010 as the first therapy to treat ATTR-PN. Following additional clinical studies, Vyndaqel/Vyndamax was approved by the US FDA for the treatment of ATTR-CM in 2019.

From Breakthrough to Progress

The approval of Vyndaqel/Vyndamax as a first-in-class treatment for ATTR-PN and ATTR-CM set the stage for an influx of new drugs that address the diseases through various modalities. This growing list includes approved siRNA-based treatments Onpattro® (patisiran) and Amvuttra® (vutisiran), antisense oligonucleotide medicines WAINUA™ (eplontersen) and Tegsedi® (inotersen), small molecule drug Attruby™ (acoramidis), and an investigational CRISPR/Cas9-based approach, NTLA-2001.

Vyndaqel/Vyndamax highlights F-Prime’s role in advancing innovative treatments that transform patient care. Its success has helped drive progress in the field, paving the way for more life-saving treatment options for patients. This journey—from groundbreaking research to a first-in-class therapy—demonstrates the power of scientific innovation and strategic investment in changing the course of rare, fatal diseases.

References:

  1. Schmidt HH, Waddington-Cruz M, Botteman MF, et al. Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve. 2018;57(5):829-837. doi:10.1002/mus.26034
  2. González-Duarte A, Conceição I, Amass L, Botteman MF, Carter JA, Stewart M. Impact of Non-Cardiac Clinicopathologic Characteristics on Survival in Transthyretin Amyloid Polyneuropathy. Neurol Ther. 2020;9(1):135-149. doi:10.1007/s40120-020-00183-7
  3. Pfizer. Understanding This Rare Disease Called ATTR Amyloidosis. Accessed January 22, 2025.
  4. Jain A, Zahra F. Transthyretin Amyloid Cardiomyopathy (ATTR-CM). StatPearls. 2023.
  5. Rozenbaum MH, Garcia A, Grima D, et al. Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies. Eur Heart J Qual Care Clin Outcomes. 2022;8(5):529-538. doi:10.1093/ehjqcco/qcab031
  6. Castaño A, Drachman BM, Judge D, Maurer MS. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev. 2015;20(2):163-178. doi:10.1007/s10741-014-9462-7

RhyGaze

RhyGaze is a cutting-edge biotechnology company based in Basel, Switzerland, and Philadelphia, Pa., USA, focused on developing gene therapies for retinal diseases causing blindness. Founded on pioneering research from the Institute of Molecular and Clinical Ophthalmology Basel (IOB), RhyGaze aims to restore vision and transform the lives of patients worldwide. IOB scientists Drs. Botond Roska, Bence György and Charles Gubser are the scientific founders of RhyGaze.

Tenvie Therapeutics

Tenvie is a biotechnology company committed to engineering small molecules that transform the treatment of neurological diseases. The company’s foundation is purpose-built with a diverse portfolio of small molecules and a proven team of CNS drug developers to rapidly deliver multiple clinical assets. Tenvie is advancing a pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseases. Its portfolio of wholly owned, highly brain-penetrant, and precision-designed peripherally restricted small molecules address three key drivers of disease: resolving inflammation, rescuing metabolic dysfunction, and restoring lysosomal function. The company’s most advanced programs target NLRP3 and SARM1, with additional programs in preclinical development. You can follow Tenvie on LinkedIn.